Positive News SentimentPositive NewsNASDAQ:CNTX Context Therapeutics (CNTX) Stock Price, News & Analysis $0.64 -0.04 (-5.60%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.73 +0.09 (+13.88%) As of 06:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Context Therapeutics Stock (NASDAQ:CNTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Context Therapeutics alerts:Sign Up Key Stats Today's Range$0.64▼$0.7050-Day Range$0.55▼$1.0052-Week Range$0.55▼$2.75Volume63,791 shsAverage Volume282,946 shsMarket Capitalization$57.66 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company OverviewContext Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Read More… Context Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreCNTX MarketRank™: Context Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 524th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingContext Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageContext Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Context Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Context Therapeutics are expected to grow in the coming year, from ($0.51) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Context Therapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Context Therapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContext Therapeutics has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Context Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.92% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.Change versus previous monthShort interest in Context Therapeutics has recently increased by 3.18%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldContext Therapeutics does not currently pay a dividend.Dividend GrowthContext Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.92% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.Change versus previous monthShort interest in Context Therapeutics has recently increased by 3.18%, indicating that investor sentiment is decreasing. News and Social Media3.2 / 5News SentimentN/A News SentimentContext Therapeutics has a news sentiment score of 1.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Context Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for CNTX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Context Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.80% of the stock of Context Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 14.03% of the stock of Context Therapeutics is held by institutions.Read more about Context Therapeutics' insider trading history. Receive CNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTX Stock News HeadlinesContext Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2025 | globenewswire.comContext Therapeutics Reports Q1 2025 Financial Results and Clinical ProgressMay 11, 2025 | msn.comWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."May 29, 2025 | Brownstone Research (Ad)CONTEXT THERAPEUTICS Earnings Results: $CNTX Reports Quarterly EarningsMay 9, 2025 | nasdaq.comContext Therapeutics Reports First Quarter 2025 Operating and Financial ResultsMay 7, 2025 | globenewswire.comContext Therapeutics Inc.: Context Therapeutics Announces Chief Medical Officer TransitionMay 7, 2025 | finanznachrichten.deContext Therapeutics Announces Chief Medical Officer TransitionMay 5, 2025 | tmcnet.comContext Therapeutics Announces Chief Medical Officer TransitionMay 5, 2025 | globenewswire.comSee More Headlines CNTX Stock Analysis - Frequently Asked Questions How have CNTX shares performed this year? Context Therapeutics' stock was trading at $1.05 at the beginning of the year. Since then, CNTX stock has decreased by 38.8% and is now trading at $0.6428. View the best growth stocks for 2025 here. How were Context Therapeutics' earnings last quarter? Context Therapeutics Inc. (NASDAQ:CNTX) posted its earnings results on Wednesday, May, 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). When did Context Therapeutics IPO? Context Therapeutics (CNTX) raised $25 million in an initial public offering (IPO) on Wednesday, October 20th 2021. The company issued 5,000,000 shares at $5.00 per share. Who are Context Therapeutics' major shareholders? Context Therapeutics' top institutional shareholders include Ally Bridge Group NY LLC (1.29%), Affinity Asset Advisors LLC (0.74%) and Landscape Capital Management L.L.C. (0.05%). Insiders that own company stock include Martin A Lehr, Jennifer Lynn Minai-Azary and Alex C Levit. View institutional ownership trends. How do I buy shares of Context Therapeutics? Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Context Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Context Therapeutics investors own include NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Celestica (CLS). Company Calendar Last Earnings5/14/2025Today5/28/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTX CIK1842952 Webwww.contexttherapeutics.com Phone267-225-7416FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$9.00 Low Stock Price Target$4.00 Potential Upside/Downside+833.4%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.96 million Net MarginsN/A Pretax MarginN/A Return on Equity-58.76% Return on Assets-55.80% Debt Debt-to-Equity RatioN/A Current Ratio36.91 Quick Ratio36.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book0.87Miscellaneous Outstanding Shares89,704,000Free Float72,718,000Market Cap$57.66 million OptionableNot Optionable Beta2.11 Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CNTX) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.